Saudi Arabia is in the midst of a national transformation under Vision 2030, a strategic roadmap for economic diversification and reducing the reliance on oil revenues. A key pillar of this strategy is the overhaul of the healthcare sector, with a primary focus on achieving national drug security. Within this framework, localization has transitioned from a simple policy to a strategic imperative for all life science and biopharma companies operating in the Kingdom.